In the first of a two-part series with TB and HIV experts at the Bill & Melinda Gates Foundation, Dr. Stefano Bertozzi, director of HIV and tuberculosis programs at the Foundation, gives his thoughts on what lies ahead this year in HIV and TB building on key developments from the past year and a half. In his role, Dr. Bertozzi oversees grants in HIV vaccine development, biomedical prevention research, diagnostics development and resistance monitoring, and strategies for introduction and scaling-up of interventions. He has held past leadership roles at UNAIDS, the World Health Organization, the World Bank, and the National Institute of Public Health (INSP) in Mexico.
The goals of controlling HIV sound like a straight forward series of three consecutive steps, one following another, when discussed in global and domestic epidemic-ending plans. […]
The announcement Wednesday of U.S. Food and Drug Administration approval of pretomanid, a new tuberculosis drug that has been part of a ground-breaking treatment regimen against […]
A randomized, multi-country clinical trial testing a regimen for treating drug-resistant tuberculosis in less than a year against the up to two-year regimen recommended by the […]
With a report showing that 2018 yielded the highest case numbers seen so far of a paralyzing condition largely among children who had been sick with […]